Skip to main content
. 2021 Nov 12;41(3):444–458. doi: 10.1038/s41388-021-01903-5

Fig. 1. The R273C-p53 allele is selectively enriched in prostate cancer.

Fig. 1

A Across cancer types (MSK-IMPACT), the TP53 gene is most frequently mutated rather than deleted (left), and these mutations are most commonly missense mutations (multiple mutations can occur in same tumor i.e., n = 4618 versus n = 4985). Missense mutations in TP53 are significantly associated with decreased overall survival (p = 1.22e−15; MSK-IMPACT study; cBioportal; right). B In prostate cancer (cBioportal; see methods for studies used), the TP53 gene is most frequently mutated compared to having a copy number variation (left), and these mutations are most commonly missense mutations (middle). Missense mutations in TP53 are significantly associated with decreased overall survival using PCa studies that include survival data (See “Materials and methods” for studies analyzed; p = 2.510e−6; right). C R273-p53 in the DNA binding domain of TP53 is the most frequently mutated residue using the studies described in (A) for all cancer types (black) and B for prostate cancer (blue). The six most frequently mutated residues in TP53 are shown. D In all cancers (MSK-IMPACT), the R273-p53 residue mutations are most frequently observed as an R273C or R273H (left). In PCa studies described in (B), R273C-p53 is the most frequently observed (right).